Bipolar Depression
Conditions
Keywords
bipolar, depression, prefrontal, cortex, antidepressant, response
Brief summary
The purpose of the study is to explore the efficacy and safety of H1-Coil deep brain rTMS in subjects with bipolar depression , currently treated with mood stabilizer and previously unsuccessfully treated with antidepressant medications
Interventions
20 daily deep rTMS treatments
inactive treatment
Sponsors
Study design
Eligibility
Inclusion criteria
• Outpatients * Diagnosed by two senior psychiatrists as suffering from bipolar depression (BP1, BP2) episode according to DSM IV using the Structured Clinical Interview for DSM-4 (SCID), with additional requirement of duration for the current episode ≥ 4 weeks and CGI ≥ 4. * Rating on HAM-D (17 items) \>20 and item 1 ≥2 at the screening visit. * Age: 18-65 years. * Gave informed consent for participation in the study. * Negative answers on safety screening questionnaire for transcranial magnetic stimulation * Taking mood stabilizing medication (e.g., lithium) on an acceptable range of dosage according to recent blood examination or antipsychotic medication as mood stabilizers prescribed by their treating physician * According to the treating physician the patient is compliant in taking the mood-stabilizing medication. * Medication resistance to at least two different antidepressant treatments, defined as resistance to a minimum of 2 antidepressant drug trials of adequate dose and duration in the current episode or previous episodes defined as a minimum level of 3 on the ATHF per antidepressant drug-trial. * Patients who have not completed antidepressant trials of adequate dose and duration due to intolerance to therapy may be included if they have demonstrated intolerance to 3 or more anti-depressant medications in the current or a previous episodes. * If currently taking antidepressant pharmacotherapy, must be clinically appropriate to discontinue treatment with those agents. * Able to tolerate psychotropic medication washout and no psychotropics during the H-coil deep brain rTMS other than benzodiazepine at equivalent dose of up to 3 mg lorazepam every day. * Right hand dominance.
Exclusion criteria
• Diagnosis as suffering from other diagnosis on axis 1 (like: schizophrenia, geriatric depression). * Diagnosis as suffering from Severe Borderline Personality Disorder or hospitalized due to exacerbation related to of borderline personality disorder. * Substantial suicidal risk as judged by the treating psychiatrist. * Attempted suicide in the past year. * Patients with a bipolar cycle of less than 30 days. * History of epilepsy or seizure in first degree relatives. * History of head injury. * History of any metal in the head (outside the mouth). * Known history of any metallic particles in the eye, implanted cardiac pacemaker or any intracardiac lines, implanted neurostimulators, surgical clips or any medical pumps. * History of frequent or severe headaches. * History of migraine. * History of hearing loss. * Known history of cochlear implants * History of substance abuse within the past 6 months (except nicotine and caffeine) or alcoholism * Pregnancy or not using a reliable method of birth control. * Unstable Systemic and metabolic disorders. * Unstable neurological or medical disease * Inadequate communication with the patient. * Under custodial care. * Participation in current clinical study or clinical study within 30 days prior to this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| change in the Hamilton depression rating scale score | 7 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Clinical antidepressant remission at the end of the treatment, defined as exit Hamilton Depression Rating Scale <10. | 7 weeks |
Countries
Israel